Dr.ObesityLA said:The GIP arm is doing real work rather than padding the label.
Pushing back on Dr.ObesityLA here. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
Correct me if the detail matters more than I have assumed.
Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.
PharmD_Rodriguez said:The "tirzepatide is simply better" summary irritates me.
There is a second half to this that has not been said yet. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after VendorMark’s answer:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
Closing the loop on my own question.
Reporting back after another eight months at the same dose. Still losing slowly, no new side effects, and no reason I can find to climb further.